Anbio Biotechnology
NNNN- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001982708
No open-market purchases or sales by Anbio Biotechnology insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $985.2K in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Anbio Biotechnology changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 5 | 10 | +5 |
| Shares | 29.6K | 68.3K | +38.7K (+130.9%) |
| Value | $936.7K | $2.54M | +$1.61M (+171.5%) |
New holders (5)
Institutions that held Anbio Biotechnology at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 10,443 | $389.0K | 0.00% |
| Millennium Management LLC | 7,080 | $263.7K | 0.00% |
| XTX Topco Ltd | 6,896 | $256.9K | 0.01% |
| HRT Financial LP | 6,013 | $223.0K | 0.00% |
| Bank of America Corp | 21 | $782 | 0.00% |
Sold out (0)
Institutions that held Anbio Biotechnology at the end of Q2 2025 and filed for Q3 2025 without it.
None.